Cleveland Clinic Names Top 10 Medical Innovations for 2014

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bionic Eye for Restoring Sight in Patients with Inherited Retina Disease Ranks No. 1 on the Annual List

October 16, 2013

Cleveland Clinic today announced its eighth annual list of Top 10 Medical Innovations that will have a major impact on improving patient care within the next year. The list includes a bionic eye, a neurostimulator for epilepsy and fecal transplantation.

The list of breakthrough devices and therapies was selected by a panel of Cleveland Clinic physicians and scientists and announced during Cleveland Clinic’s 2013 Medical Innovation Summit.

The Top 10 Medical Innovations for 2014 are:

  1. RETINAL PROSTHESIS SYSTEM – EARLY STAGE BIONIC EYE

    After two decades of development and testing and more than $200 million in funding, the Food and Drug Administration approved an early-stage bionic eye for severe retinitis pigmentosa (RP) in 2013 that combined a surgically implanted 60-electrode retinal prosthesis, video-camera-enabled glasses, and a video processing unit.

  2. GENOME-GUIDED SOLID TUMOR DIAGNOSTICS

    A variety of genomic-based cancer tests are now available that, without surgery, can analyze the genes in a person’s cancer tumor and predict both the biology and aggressiveness of the cancer.

  3. RESPONSIVE NEUROSTIMULATOR FOR INTRACTABLE EPILEPSY

    An implanted neurological device that can significantly reduce the frequency of epileptic seizures gained the unanimous backing of an FDA neurological device advisory panel in 2013. Surgically implanted under the scalp, the device delivers short electrical pulses to interrupt the triggers before seizure symptoms can occur.

  4. DIRECT-ACTING ANTIVIRAL ORAL HEPATITIS C DRUGS

    Sofosbuvir, the first all-oral hepatitis C treatment, is moving through the final stages of FDA approval. This medication would be the first of a new generation of hepatitis C drugs called direct-acting antivirals, which can improve treatment response rates to 90 percent or higher.

  5. PERIOPERATIVE DECISION SUPPORT SYSTEM

    A new anesthesia management system that combines the latest in computer technology and microelectronics is now available to meet the demands of modern surgery and improve the standard of care.

  6. FECAL MICROBIOTA TRANSPLANTATION

    Many gastroenterologists are now employing fecal microbiota transplantation—the use of human stool transplants—to battle C.diff in those patients who do not respond to standard drug therapy.

  7. RELAXIN FOR ACUTE HEART FAILURE

    A synthetic version of the naturally occurring hormone, human relaxin-2, which is widely associated with pregnancy, has proven that it can improve acute heart failure symptoms after being infused over a 48-hour period in the hospital following a heart failure episode or a heart attack.

  8. COMPUTER-ASSISTED PERSONALIZED SEDATION SYSTEM

    A new sedation system is a first-of-a-kind device in the world that allows non-anesthesia professionals to administer the drug propofol during colonoscopy and esophagogastroduodenoscopy (EGD) procedures.

  9. TMAO: A NOVEL BIOMARKER FOR HEART ATTACK, STROKE RISK

    Scientists have discovered what may be an important new biomarker for heart disease that serves as an accurate screening tool for predicting future risks of heart attack, stroke, and death in persons not otherwise identified by traditional risk factors and blood tests. The novel biomarker is called TMAO, or trimethylamine N-oxide, and it’s a microbial byproduct of intestinal bacteria.

  10. B-CELL RECEPTOR PATHWAY TO TREAT BLOOD CANCERS

    For treatment of low-grade B-cell lymphomas and leukemias, there is now B-cell receptor pathway inhibitors that interfere with cancer cell division by focusing on proteins involved in signaling pathways. By effectively blocking signals that tell cancer cells to grow and divide uncontrollably, these targeted cancer therapies can help stop cancer progression while preserving normal, healthy cells.

About Cleveland Clinic

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, currently under construction, Cleveland Clinic Abu Dhabi. In 2012, there were 5.1 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. Visit us at http://my.clevelandclinic.org. Follow us at http://www.twitter.com/ClevelandClinic.

Media Contact

Joe Milicia, 216.312.0591, milicij2@ccf.org

Cleveland Clinic Mobile Site